SCHEMBL30796852

SCHEMBL30796852

O=C(Cc1cc(F)cc(F)c1)Nn1nc(Cl)c2ccccc2c1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TRPV1 Q8NER1 1/20 0.41
▸ SIGMAR1 Q99720 1/20 0.41
▸ AKR1B1 P15121 3/20 0.40
▸ SMN1; SMN2 Q16637 3/20 0.40
▸ LMNA P02545 2/20 0.40
▸ USP2 O75604 1/20 0.40
▸ KDM4E B2RXH2 2/20 0.39
▸ HPGD P15428 2/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ MAPT P10636 1/20 0.39
▸ ABCB1 P08183 1/20 0.38
▸ RIPK1 Q13546 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ NR2F2 P24468 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ AURKA O14965 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ PSEN1 P49768 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1789011 1.00 TRPV1 (0.41) TRPV1SIGMAR1AKR1B1SMN1; SMN2LMNA
SCHEMBL1786512 0.86 KMT2A (0.48) AKR1B1SMN1; SMN2LMNAUSP2ALDH1A1
SCHEMBL30795566 0.86 KMT2A (0.48) AKR1B1SMN1; SMN2LMNAUSP2ALDH1A1
SCHEMBL30794712 0.85 LMNA (0.47) LMNAALDH1A1MAPTPOLBHTT
SCHEMBL1789074 0.85 LMNA (0.47) LMNAALDH1A1MAPTPOLBHTT
SCHEMBL1785726 0.84 KDM4E (0.54) AKR1B1LMNAKDM4EHPGDALDH1A1
SCHEMBL30824700 0.84 KDM4E (0.54) AKR1B1LMNAKDM4EHPGDALDH1A1
SCHEMBL30795437 0.84 ADRA1A (0.45) SMN1; SMN2LMNAUSP2KDM4EHPGD
SCHEMBL1789505 0.84 ADRA1A (0.45) SMN1; SMN2LMNAUSP2KDM4EHPGD
SCHEMBL30796353 0.84 MAPT (0.50) AKR1B1SMN1; SMN2LMNAUSP2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4584250-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS Biohaven Therapeutics Ltd. (VG) 2025-07-16 — — EP disclosed
EP-4580679-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS Biohaven Therapeutics Ltd. (VG) 2025-07-09 — — EP disclosed
WO-2024054811-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-14 — — WO disclosed
WO-2024054807-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-14 — — WO disclosed
WO-2024050389-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-07 — — WO disclosed
Send feedback